In fact, it has been reported that ADO reduces NF-κB activation in T cells and monocytes of COVID-19 patients in vitro (21), and the administration of an A2aR agonist attenuated the production of pro-inflammatory cytokines in SARS-CoV-2 mice infection model (77). Here, ADORA2A is linked to COVID-19.